ProMIS Neurosciences, Inc. (PMN)
| Market Cap | 29.50M +42.5% |
| Revenue (ttm) | n/a |
| Net Income | -38.81M |
| EPS | -5.65 |
| Shares Out | 8.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 156,539 |
| Open | 3.790 |
| Previous Close | 3.480 |
| Day's Range | 2.980 - 3.790 |
| 52-Week Range | 2.780 - 27.400 |
| Beta | -0.21 |
| Analysts | Strong Buy |
| Price Target | 42.33 (+1,186.63%) |
| Earnings Date | Nov 12, 2026 |
About PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PMN stock is "Strong Buy." The 12-month stock price target is $42.33, which is an increase of 1,186.63% from the latest price.
News
ProMIS Neurosciences Earnings Call Transcript: Q3 2026
PRECISE-AD 12-month top-line data remain expected in Q1 2027, with management emphasizing interim safety and biomarker signals for PMN310. Q3 cash of $44.1 million is expected to fund operations through 2027; next-stage plans depend on trial results and FDA feedback.
ProMIS Neurosciences Earnings release: Q3 2026
ProMIS Neurosciences released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
ProMIS Neurosciences Quarterly report: Q3 2026
ProMIS Neurosciences has published its Q3 2026 quarterly earnings report on November 12, 2026.
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
PRECISE-AD Phase 1b clinical trial in Alzheimer's patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes da...
ProMIS Neurosciences Transcript: Stifel 2026 Healthcare Conference 2026
The 144-patient PMN310 Phase Ib trial is expected to report topline data in Q1 next year; its six-month blinded interim showed no ARIA-E and decreases in p-tau217 and MTBR. Development planning includes subQ dosing and Phase III design, contingent on final results and FDA feedback.
ProMIS Neurosciences Slides: Investor presentation
ProMIS Neurosciences has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
ProMIS Neurosciences Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
PMN310’s blinded six-month interim results showed zero ARIA-E cases, placebo-like ARIA-H and decreases in two biomarkers. Top-line Phase I-B data are guided for Q1 2027; results will inform whether to pursue a registration-stage study.
ProMIS Neurosciences to Participate in Upcoming Conferences in November
CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfol...
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxi...
ProMIS Neurosciences price target lowered to $15 from $29 at Roth Capital
Roth Capital lowered the firm’s price target on ProMIS Neurosciences (PMN) to $15 from $29 and keeps a Buy rating on the shares following Acumen’s (ABOS) failed Phase 2 study…
Promis Neurosciences Inc trading resumes
12:22 EDT Promis Neurosciences (PMN) Inc trading resumes
Promis Neurosciences Inc trading halted, volatility trading pause
12:12 EDT Promis Neurosciences (PMN) Inc trading halted, volatility trading pause
ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer
ProMIS Neurosciences (PMN) announced the appointment of Ivana Rubino as chief commercial officer, effective October 5. During her time at Biogen (BIIB) and F. Hoffmann-La Roche, Rubino led and helped…
ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer's clinical development, launch readiness, commercialization and global medical strategy
ProMIS Neurosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A novel antibody therapy for Alzheimer's demonstrated strong interim safety and promising biomarker engagement in a large phase I-B trial, with zero ARIA-E cases and a 15% decline in p-tau217. Top-line results are expected in Q1 2027, supported by robust funding and a differentiated technology platform.
ProMIS Neurosciences Transcript: Moody Capital Disruptive Growth & Life Science Conference
A novel antibody therapy for Alzheimer's showed zero cases of brain swelling and strong biomarker engagement in a robust phase I-B trial, with top-line results expected in Q1 2027. The differentiated approach targets only toxic protein forms, offering a safer profile than current drugs.
ProMIS Neurosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
PMN310, a differentiated antibody targeting toxic amyloid-beta oligomers, showed strong interim safety and biomarker signals in a phase I-B Alzheimer's study, with top-line results expected in Q1 2027. The company is well-funded, advancing a robust pipeline, and planning for phase III and commercial expansion.
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfol...
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
Roth Capital lowered the firm’s price target on ProMIS Neurosciences (PMN) to $29 from $30 and keeps a Buy rating on the shares. The company’s central catalyst remains the unblinded…
ProMIS Neurosciences reports Q2 EPS ($1.28), consensus ($1.90)
“The second quarter of 2026 was a pivotal period for ProMIS, as we continued to advance PRECISE-AD while maintaining a strong financial position,” said Neil Warma, President and Chief Executive…
ProMIS Neurosciences price target raised to $100 from $69 at Guggenheim
Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $100 from $69 and keeps a Buy rating on the shares. The firm cites “increased conviction” in the PMN310…
ProMIS Neurosciences Earnings Call Transcript: Q2 2026
Six-month interim data from the phase I-B PRECISE-AD trial showed a strong safety profile for PMN310, with no ARIA-E cases and favorable biomarker trends, supporting its differentiated approach in Alzheimer's. Cash runway extends through 2027, with pipeline programs advancing.
ProMIS Neurosciences Quarterly report: Q2 2026
ProMIS Neurosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
ProMIS Neurosciences Earnings release: Q2 2026
ProMIS Neurosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therap...